Oculus imaging device approved by FDA

October 27, 2008

Article

The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.

The PARK 1 (Pachymeter/Autorefractor/Keratometer) imaging device (Oculus) has received premarket approval from the FDA.

The slim, ergonomically-designed device features a 5.7" LCD display, and comprises an autorefractor combined with a Scheimpflug based non-contact pachymeter, to photograph and measure corneal thickness and lens refractive power. It can be set to PARK, ARK or P measurement modes.

The PARK 1 will be launched officially at this year's American Academy of Ophthalmology (AAO) meeting, which is to be held on November 8–11 in Atlanta, GA, US.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos

Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times

SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium

Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.

Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe

Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe

Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)

Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium

At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients

$At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery$

Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.

Related Content

A brain and a fungus mushroom both depicted in illustration. Concept image for fungal infection and diabetic eye disease. Image credit: ©Anson – stock.adobe.com – generated with AI

Fungal infection and vision impact in patients with diabetic eye disease

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

A magnifying glass enhances stocks on a chart. Concept image for global commercialisation agreement, pharmaceutical distribution in eastern and western hemispheres, Europe and EMEA. Image credit: ©Asma – stock.adobe.com

Nicox and Kowa enter commercialisation agreement for NCX 470 glaucoma eye drop

Martin David Harp

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

The flags of the European Union (left) and Germany (right), in Berlin, in front of the German parliament. Concept image for European Commission, European Medicines Agency and European myopia atropine drug launch. Image credit: ©respiro888 – stock.adobe.com

Germany serves as European launch point for low-dose atropine from Santen (Ryjunea)

Emily Kaiser Maharjan

The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

Abigail Lewis, editorial intern

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

Frank Kerkhoff, MD, PhD, and visual acuity charts following implantation with the Johnson and Johnson Tecnis Odyssey lens.

Q&A: Early research findings and clinical experiences with a new multifocal IOL

Frank Kerkhoff, MD, PhD ;Hattie Hayes

Frank Kerkhoff, MD, shares his experiences with the Johnson & Johnson Tecnis Odyssey lens

Related Content

A brain and a fungus mushroom both depicted in illustration. Concept image for fungal infection and diabetic eye disease. Image credit: ©Anson – stock.adobe.com – generated with AI

Fungal infection and vision impact in patients with diabetic eye disease

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

A magnifying glass enhances stocks on a chart. Concept image for global commercialisation agreement, pharmaceutical distribution in eastern and western hemispheres, Europe and EMEA. Image credit: ©Asma – stock.adobe.com

Nicox and Kowa enter commercialisation agreement for NCX 470 glaucoma eye drop

Martin David Harp

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

The flags of the European Union (left) and Germany (right), in Berlin, in front of the German parliament. Concept image for European Commission, European Medicines Agency and European myopia atropine drug launch. Image credit: ©respiro888 – stock.adobe.com

Germany serves as European launch point for low-dose atropine from Santen (Ryjunea)

Emily Kaiser Maharjan

The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

Abigail Lewis, editorial intern

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

Frank Kerkhoff, MD, PhD, and visual acuity charts following implantation with the Johnson and Johnson Tecnis Odyssey lens.

Q&A: Early research findings and clinical experiences with a new multifocal IOL

Frank Kerkhoff, MD, PhD ;Hattie Hayes

Frank Kerkhoff, MD, shares his experiences with the Johnson & Johnson Tecnis Odyssey lens

Editorial Board

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.